Caregen Stock Forecast for 2023 - 2025 - 2030
Updated on 04/30/2024
Caregen Fair Value Forecast for 2023 - 2025 - 2030
In the last year, Caregen's Price has decreased by 100.00%, from ₩22.26k to ₩0.00. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach ₩0.00 – an increase of 100.00%. Over the next six years, experts anticipate that Fair Value growth for Caregen will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A207940 Stock Forecast | Samsung Biologics | Buy |
7
|
₩775.00k | Buy/Sell | ₩0.00B | 35.48% |
| A068270 Stock Forecast | Celltrion | Outperform |
16
|
₩183.70k | Buy/Sell | ₩215.28k | 25.20% |
| A091990 Stock Forecast | Celltrion Healthcare | - |
12
|
₩75.90k | Buy/Sell | ₩90.17k | -100.00% |
| A196170 Stock Forecast | ALTEOGEN | Outperform |
6
|
₩176.50k | Buy/Sell | ₩83.33k | -20.68% |
| A068760 Stock Forecast | Celltrion Pharm | - |
11
|
₩92.20k | Buy/Sell | ₩11.33k | -100.00% |
Caregen Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Revenue for Caregen has grown by 14.60%, going from ₩60.30B to ₩69.10B. For the next year, 0 analysts project Caregen's Revenue to drop by 8.98%, reaching ₩62.89B. By 2030, professionals believe that Caregen's Revenue will decrease by 8.62%, reaching ₩63.14B – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A141080 Stock Forecast | LegoChem Biosciences | Outperform |
7
|
₩66.80k | Buy/Sell | ₩66.50k | 37.72% |
| A006280 Stock Forecast | GC Biopharma | Buy |
16
|
₩115.10k | Buy/Sell | ₩146.43k | 25.11% |
| A007390 Stock Forecast | NatureCell | - |
0
|
₩7.29k | Buy/Sell | ₩0.00 | -100.00% |
.jpg)
Caregen Dividend per Share Forecast for 2023 - 2025 - 2030
In the last year, Caregen's Dividend per Share has fallen from ₩2000.00 to ₩540.00 – a 73.00% decrease. In the next year, analysts predict that Dividend per Share will reach ₩2000.00 – an increase of 270.37%. For the next eight years, the forecast is for Dividend per Share to grow by 476.47%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A256840 Stock Forecast | BNC Korea | - |
0
|
₩3.56k | Buy/Sell | ₩0.00 | -100.00% |
| A298380 Stock Forecast | ABL Bio | Outperform |
6
|
₩26.40k | Buy/Sell | ₩37.00k | 40.15% |
| A115450 Stock Forecast | HLB Therapeutics | - |
6
|
₩11.60k | Buy/Sell | ₩20.77k | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A214450 Stock Forecast | PharmaResearch | Outperform |
16
|
₩128.50k | Buy/Sell | ₩165.00k | 36.19% |
| A086900 Stock Forecast | Medy-Tox | Outperform |
8
|
₩136.90k | Buy/Sell | ₩335.00k | 170.27% |
| A293780 Stock Forecast | AptaBio Therapeutics |
0
|
₩7.62k | Buy/Sell | ₩0.00 | -100.00% |
Caregen EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Caregen's EBITDA has grown, increasing from ₩34.06B to ₩37.05B – an increase of 8.78%. According to 0 major analysts, Caregen's EBITDA will fall by 8.10% in the next year, reaching ₩34.05B. Professionals believe that By 2030, Caregen's EBITDA will fall to ₩34.13B– a 7.90% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A182400 Stock Forecast | NKMAX CO. | - |
7
|
₩5.66k | Buy/Sell | ₩0.00 | -100.00% |
| A144510 Stock Forecast | GC Cell | - |
11
|
₩38.40k | Buy/Sell | ₩74.00k | -100.00% |
| A041960 Stock Forecast | Komipharm International | - |
6
|
₩4.39k | Buy/Sell | ₩0.00 | -100.00% |
Caregen EBIT Forecast for 2023 - 2025 - 2030
Caregen's EBIT has increased by 5.08% In the last two years, going from ₩31.98B to ₩33.60B. In the next year, 0 analysts estimate that Caregen's EBIT will decrease by 6.31%, reaching ₩31.48B. According to professional forecasts, in 2030, Caregen's EBIT will decrease by 6.25%, reaching ₩31.50B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A065660 Stock Forecast | Anterogen.Co.,Ltd. | - |
7
|
₩14.01k | Buy/Sell | ₩0.00 | -100.00% |
| A290650 Stock Forecast | L&C Bio | - |
17
|
₩20.40k | Buy/Sell | ₩0.00 | -100.00% |
| A235980 Stock Forecast | MedPacto | - |
4
|
₩9.79k | Buy/Sell | ₩23.00k | -100.00% |
Caregen EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last year, Caregen's EPS has decreased by 100.00%, from ₩750.00 to ₩0.00. In the coming year, analysts are expecting an increase in EPS, predicting it will reach ₩0.00 – an increase of 100.00%. Over the next six years, experts anticipate that EPS growth for Caregen will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A087010 Stock Forecast | Peptron | - |
6
|
₩28.25k | Buy/Sell | ₩35.00k | -100.00% |
| A031390 Stock Forecast | Green Cross Cell | - |
14
|
₩38.55k | Buy/Sell | ₩80.00k | -100.00% |
| A299660 Stock Forecast | Cellid, | - |
5
|
₩4.27k | Buy/Sell | ₩0.00 | -100.00% |
.jpg)